M
MSI Methylation Sciences
Developing New Medicines and Leveraging Known Pharmacology
About MSI Methylation Sciences
Methylation Sciences Inc. (MSI) is a clinical stage pharmaceutical company dedicated to developing new products based on molecules that have clinical proof of concept but are yet to be fully exploited in major pharmaceutical markets. The company's primary focus is on creating superior oral formulations of S-adenosylmethionine, a naturally occurring molecule essential for the one-carbon cycle in the body. MSI's lead product targets Major Depressive Disorder (MDD), a significant mental health condition affecting millions globally.
MSI operates in the pharmaceutical industry, specifically within the niche of mental health treatments. The company serves patients suffering from MDD and aims to provide innovative solutions where existing treatments may fall short. The business model revolves around advancing clinical trials to bring their products to market, securing investments, and forming strategic partnerships to fund development and commercialization efforts.
Revenue generation for MSI primarily comes from investment agreements and potential future sales of their pharmaceutical products once they receive regulatory approval. The company has experienced both challenges and successes in securing funding, as evidenced by their arbitration victory over Quark, resulting in a $20 million award.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2007
- Headquarters
- Burnaby, Canada
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2016 | $30M | $120M | Quark Venture | — |
| SERIES A✓Equity / VC | Sep 2011 | $15M | $59M | INventages Venture Capital | — |
Growth signals
Latest recorded traffic for MSI Methylation Sciences is 130 monthly website visits. MSI Methylation Sciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
GrowthWorks Capital
Series A2 investors entered at this stage
INventages Venture Capital
Quark Venture
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about MSI Methylation Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MSI Methylation Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.